Get all your news in one place.
100's of premium titles.
One app.
Start reading
AAP
AAP
Business
Derek Rose

CSL's potential heart attack drug a dud in huge trial

CSL had high hopes for CSL112 and had even prepared manufacturing facilities for its production. (James Ross/AAP PHOTOS)

CSL says the most ambitious clinical trial in its 107-year history has failed to show any benefit to a highly touted potential treatment aimed at stopping secondary heart attacks.

CSL has spent two decades and nearly $1 billion developing CSL112, a treatment derived from human blood plasma.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.